ArticleBMC gastroenterology2025
Cancer disparities in lean vs. non-lean MASH: insight from a national inpatient sample.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MASLD: Spatial Mechanisms and New Therapeutics.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate cancer disparities between lean (BMI < 25 kg/m²; < 23 kg/m² for Asians) and non-lean metabolic dysfunction-associated steatohepatitis (MASH) by analyzing the prevalence of the 18 most common cancers in a large U.S. COHORT:
methodsThis retrospective cohort study utilized the National Inpatient Sample (2016-2020) with weighted data to project findings to the general population. Patients were categorized as lean or non-lean based on BMI during hospitalization, excluding alternative etiologies via validated algorithms. Outcomes included composite cancer prevalence (primary) and individual cancer prevalence (secondary). Multivariable logistic regression was applied to assess differences.
resultsAmong 34,955,252 U.S. hospitalizations, 539,275 patients had MASH (mean age: 64 years for lean vs. 58.8 years for non-lean; >60% female). Lean MASH hospitalizations had higher odds of lung (aOR 1.76, CI 1.33-2.10, P < 0.001), colon (aOR 1.23, CI 1.02-1.48, P = 0.027), kidney (aOR 1.27, CI 1.10-1.44, P = 0.001), liver (aOR 1.21, CI 1.12-1.31, P < 0.001), and cervical cancers (aOR 3.25, CI 1.07-9.86, P = 0.037), as well as non-Hodgkin's lymphoma (aOR 1.28, CI 1.08-1.51, P = 0.004), but lower odds of endometrial cancer (aOR 0.35, CI 0.25-0.50, P < 0.001).
conclusionLean MASH hospitalizations are linked to higher odds of several cancers despite lower BMI, underscoring the need for a nuanced understanding of cancer risks in MASH. BMI alone may not fully capture oncologic risk in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.